These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 19380837)

  • 21. Dispelling myths and removing barriers about insulin in type 2 diabetes.
    Meece J
    Diabetes Educ; 2006; 32(1 Suppl):9S-18S. PubMed ID: 16439485
    [No Abstract]   [Full Text] [Related]  

  • 22. Glycemic Targets in Diabetes Care: Emerging Clarity after Accord.
    Buse JB
    Trans Am Clin Climatol Assoc; 2015; 126():62-76. PubMed ID: 26330660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysis.
    Davidson JA; Liebl A; Christiansen JS; Fulcher G; Ligthelm RJ; Brown P; Gylvin T; Kawamori R
    Clin Ther; 2009 Aug; 31(8):1641-51. PubMed ID: 19808125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [New, expensive antidiabetics for the treatment of type-2 diabetes--contra].
    Nawroth P
    Dtsch Med Wochenschr; 2010 May; 135(18):923. PubMed ID: 20425679
    [No Abstract]   [Full Text] [Related]  

  • 25. [Hypoglycemia--simply annoying or dangerous?].
    Kern W
    MMW Fortschr Med; 2016 Jun; 158(11):67-70. PubMed ID: 27271419
    [No Abstract]   [Full Text] [Related]  

  • 26. Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes.
    Lipska KJ; Krumholz H; Soones T; Lee SJ
    JAMA; 2016 Mar; 315(10):1034-45. PubMed ID: 26954412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
    Ilag LL; Kerr L; Malone JK; Tan MH
    Clin Ther; 2007 Jun; 29(6 Pt 1):1254-70. PubMed ID: 18036388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Increased risk of hypoglycemia in the elderly and frail. Steep decrease of HbA1c is not always advisable].
    Pampel SL
    MMW Fortschr Med; 2011 Jul; 153(29-31):20. PubMed ID: 21830731
    [No Abstract]   [Full Text] [Related]  

  • 29. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Importance of glucose control.
    Edelman SV
    Med Clin North Am; 1998 Jul; 82(4):665-87. PubMed ID: 9706116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Special considerations for treatment of type 2 diabetes mellitus in the elderly.
    Fravel MA; McDanel DL; Ross MB; Moores KG; Starry MJ
    Am J Health Syst Pharm; 2011 Mar; 68(6):500-9. PubMed ID: 21378298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Guidelines ease up on glycemic control for some patients with type 2 diabetes.
    Mitka M
    JAMA; 2012 Jun; 307(21):2243-4. PubMed ID: 22706812
    [No Abstract]   [Full Text] [Related]  

  • 33. Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: A perspective on glucose-lowering interventions.
    Roussel R; Steg PG; Mohammedi K; Marre M; Potier L
    Diabetes Obes Metab; 2018 Feb; 20(2):238-244. PubMed ID: 28597588
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA.
    Hunt B; Mocarski M; Valentine WJ; Langer J
    J Med Econ; 2017 Jul; 20(7):663-670. PubMed ID: 28294641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucose lowering and cardiovascular disease: what do we know and what should we do?
    Cheng AY; Leiter LA
    Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S25-31. PubMed ID: 20489417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intensive Glycemic Control in Type 2 Diabetes Mellitus -- A Balancing Act of Latent Benefit and Avoidable Harm: A Teachable Moment.
    Rodriguez-Gutierrez R; Lipska KJ; McCoy RG
    JAMA Intern Med; 2016 Mar; 176(3):300-1. PubMed ID: 26882223
    [No Abstract]   [Full Text] [Related]  

  • 37. Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes.
    Lau DC; Teoh H
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S148-54. PubMed ID: 26654858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glycemic targets and medication limitations for type 2 diabetes mellitus in the older adult.
    Thompson AM; Linnebur SA; Vande Griend JP; Saseen JJ
    Consult Pharm; 2014 Feb; 29(2):110-23. PubMed ID: 24513421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging care for type 2 diabetes: using insulin to reach lower glycemic goals.
    Feinglos MN; Bethel MA
    Cleve Clin J Med; 2005 Sep; 72(9):791-9. PubMed ID: 16193826
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Lewin AJ; Arvay L; Liu D; Patel S; von Eynatten M; Woerle HJ
    Clin Ther; 2012 Sep; 34(9):1909-19.e15. PubMed ID: 22939034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.